Can vaccines save sight?

Article

Vaccines may have a role to play against corneal and external ocular disease, because of their success in preventing systemic diseases, according to a presentation given during Cornea Day at the annual meeting of the American Society of Cataract and Refractive Surgery earlier this year.

Vaccines may have a role to play against corneal and external ocular disease, because of their success in preventing systemic diseases, according to a presentation given during Cornea Day at the annual meeting of the American Society of Cataract and Refractive Surgery earlier this year.

Minas T. Coroneo, MD, chairman of the Department of Ophthalmology at the University of New South Wales, Sydney, Australia, discussed the vaccines for herpes zoster virus (HZV, which causes shingles and chicken pox) and human papilloma virus (HPV) infections.

The chance of getting an HZV infection during an individual's lifetime is 10–25%, and the associated complications, such as loss of sight, are substantial. The incidence of infection increases with age, and the length of time of the attacks is greater in older patients.“HZV and HPV are highly prevalent and are associated with high morbidity and cost,” said Dr Coroneo.

The Shingles Prevention Study found that a vaccine reduces the incidence of post-herpetic neuralgia, the impact of which is substantial for elderly patients. Ophthalmologists, said Dr Coroneo, should be interested in preventing post-herpetic neuralgia as cranial dermatomes are the second most commonly affected site (following thoracic infections) and because of the potential for loss of sight.

A strategy to prevent shingles is important because available treatments do not prevent post-herpetic neuralgia, which, when left untreated, is associated with further complications. In clinical trials, vaccines have successfully reduced the incidence of HZV infection and post-herpetic neuralgia for up to five years after vaccination.“Vaccines work by inducing specific memory T-cells that normally decrease in number with aging,” Dr Coroneo concluded.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
Related Content
© 2025 MJH Life Sciences

All rights reserved.